| Autor: |
Khanna S; Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Schloss Birlinghoven, Sankt Augustin, 53754, Germany.; Bonn-Aachen International Center for Information Technology (B-IT), University of Bonn, 53113, Bonn, Germany., Domingo-Fernández D; Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Schloss Birlinghoven, Sankt Augustin, 53754, Germany.; Bonn-Aachen International Center for Information Technology (B-IT), University of Bonn, 53113, Bonn, Germany., Iyappan A; Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Schloss Birlinghoven, Sankt Augustin, 53754, Germany.; Bonn-Aachen International Center for Information Technology (B-IT), University of Bonn, 53113, Bonn, Germany., Emon MA; Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Schloss Birlinghoven, Sankt Augustin, 53754, Germany.; Bonn-Aachen International Center for Information Technology (B-IT), University of Bonn, 53113, Bonn, Germany., Hofmann-Apitius M; Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Schloss Birlinghoven, Sankt Augustin, 53754, Germany.; Bonn-Aachen International Center for Information Technology (B-IT), University of Bonn, 53113, Bonn, Germany., Fröhlich H; Bonn-Aachen International Center for Information Technology (B-IT), University of Bonn, 53113, Bonn, Germany. holger.froehlich@ucb.com.; UCB Biosciences GmbH, Alfred-Nobel Str. 10, 40789, Monheim, Germany. holger.froehlich@ucb.com. |
| Abstrakt: |
Alzheimer's Disease (AD) is among the most frequent neuro-degenerative diseases. Early diagnosis is essential for successful disease management and chance to attenuate symptoms by disease modifying drugs. In the past, a number of cerebrospinal fluid (CSF), plasma and neuro-imaging based biomarkers have been proposed. Still, in current clinical practice, AD diagnosis cannot be made until the patient shows clear signs of cognitive decline, which can partially be attributed to the multi-factorial nature of AD. In this work, we integrated genotype information, neuro-imaging as well as clinical data (including neuro-psychological measures) from ~900 normal and mild cognitively impaired (MCI) individuals and developed a highly accurate machine learning model to predict the time until AD is diagnosed. We performed an in-depth investigation of the relevant baseline characteristics that contributed to the AD risk prediction. More specifically, we used Bayesian Networks to uncover the interplay across biological scales between neuro-psychological assessment scores, single genetic variants, pathways and neuro-imaging related features. Together with information extracted from the literature, this allowed us to partially reconstruct biological mechanisms that could play a role in the conversion of normal/MCI into AD pathology. This in turn may open the door to novel therapeutic options in the future. |
